Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $35.00 at HC Wainwright

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its target price boosted by HC Wainwright from $30.00 to $35.00 in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

CPRX has been the topic of a number of other research reports. Stephens started coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price target on the stock. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 3rd. Bank of America reiterated a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday. Finally, Truist Financial raised their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $32.86.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX opened at $21.92 on Friday. The company has a fifty day moving average of $21.77 and a two-hundred day moving average of $19.90. The company has a market capitalization of $2.61 billion, a PE ratio of 18.58, a P/E/G ratio of 3.35 and a beta of 0.79. Catalyst Pharmaceuticals has a 1 year low of $13.12 and a 1 year high of $24.27.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now owns 686,996 shares in the company, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock worth $1,754,140 over the last ninety days. 11.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CPRX. Natixis Advisors LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth approximately $513,000. Rhumbline Advisers grew its holdings in Catalyst Pharmaceuticals by 3.5% in the second quarter. Rhumbline Advisers now owns 323,769 shares of the biopharmaceutical company’s stock valued at $5,015,000 after purchasing an additional 10,805 shares during the last quarter. TD Asset Management Inc purchased a new position in shares of Catalyst Pharmaceuticals in the second quarter valued at $254,000. Arizona State Retirement System raised its stake in shares of Catalyst Pharmaceuticals by 2.2% during the 2nd quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock worth $461,000 after buying an additional 654 shares during the last quarter. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth about $70,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.